MMW - Fortschritte der Medizin

, Volume 160, Issue 6, pp 65–70 | Cite as

Herzschutz bei Diabetes

Sind manche Antidiabetika besser als andere?

FORTBILDUNG . SEMINAR

Aufgrund der bemerkenswerten Datenlage der seit 2015 publizierten großen Outcome-Studien im Bereich des Typ-2-Diabetes mellitus [1, 2] wäre eine (vor-)schnelle Beantwortung der oben formulierten Frage verlockend. Doch ganz so einfach ist es nicht, meint unser Autor.

Cardioprotection and diabetes mellitus — which antidiabetic agents seem to do better

Keywords

Cardiovascular mortality antidiabetic treatment SGLT-2-inhibitors GLP-1- agonists 

Literatur

  1. 1.
    Zinman B et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.CrossRefGoogle Scholar
  2. 2.
    Marso S et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–22.CrossRefGoogle Scholar
  3. 3.
    The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.CrossRefGoogle Scholar
  4. 4.
    The ADVANCE Collaborative Group. Intensive blood glucose control and vascular out-comes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72CrossRefGoogle Scholar
  5. 5.
    Nissen SE et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–71CrossRefGoogle Scholar
  6. 6.
    Effect of intensive blood-glucose control with metformin on complications in over-weightpatients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854–65. Erratum in: Lancet1998 Nov 7;352(9139):1558.CrossRefGoogle Scholar
  7. 7.
    Roumie CL et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012 Nov 6;157(9):601–10.CrossRefGoogle Scholar
  8. 8.
    Boussageon R, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204.CrossRefGoogle Scholar
  9. 9.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837–53. Erratum in: Lancet 1999 Aug 14;354(9178):602.CrossRefGoogle Scholar
  10. 10.
    Forst T et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013; 10: 302–1CrossRefGoogle Scholar
  11. 11.
    Roumie CL et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Annals of Internal Medicine (2012; 157: 601–10)CrossRefGoogle Scholar
  12. 12.
    Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070–2080CrossRefGoogle Scholar
  13. 13.
    Simpson SH et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 43–51.CrossRefGoogle Scholar
  14. 14.
    Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–26.CrossRefGoogle Scholar
  15. 15.
    Green JB et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232–42CrossRefGoogle Scholar
  16. 16.
    Holman RR et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239.CrossRefGoogle Scholar
  17. 17.
    Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabe-tes. N Engl J Med. 2016 Nov 10;375(19):1834–1844. Epub 2016 Sep 15.CrossRefGoogle Scholar
  18. 18.
    Kosiborod M et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodi-um-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodi-um-Glucose Cotransporter-2 Inhibitors). Circulation. 2017 Jul 18;136(3):249–259.CrossRefGoogle Scholar
  19. 19.
    Haffner SM et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34CrossRefGoogle Scholar
  20. 20.
    Ronco C et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52(19):1527–39. Review.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.München-DenningMünchenDeutschland

Personalised recommendations